Sintx Technologies (NASDAQ:SINT) and Bioventus (NASDAQ:BVS) Critical Contrast

Sintx Technologies (NASDAQ:SINT) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Sintx Technologies and Bioventus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1	0	3	0	2.50
Bioventus	0	0	6	0	3.00

Sintx Technologies currently has a consensus price target of $9.50, suggesting a potential upside of 350.24%. Bioventus has a consensus price target of $16.80, suggesting a potential upside of 28.64%. Given Sintx Technologies’ higher possible upside, equities research analysts clearly believe Sintx Technologies is more favorable than Bioventus.

Profitability

This table compares Sintx Technologies and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-848.20%	-354.44%	-115.37%
Bioventus	9.36%	28.08%	9.82%

Valuation and Earnings

This table compares Sintx Technologies and Bioventus”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02 million	8.94	-$10.36 million	($4.91)	-0.43
Bioventus	$568.09 million	1.93	$22.73 million	$0.77	16.96

Bioventus has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by insiders. Comparatively, 33.5% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Bioventus beats Sintx Technologies on 11 of the 13 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.